Results 281 to 290 of about 269,027 (363)

Incidence and Impact of Myocarditis in Genetic Cardiomyopathies: Inflammation as a Potential Therapeutic Target. [PDF]

Genes (Basel)
Lutokhina Y, Zaklyazminskaya E, Kogan E, Nartov A, Nartova V, Blagova O.   +5 more
europepmc   +1 more source

Dilated cardiomyopathy evaluation with Imagenomics: combining multimodal cardiovascular imaging and genetics

ESC Heart Failure, EarlyView.
Systematic approach to dilated cardiomyopathy diagnosis. Dilated cardiomyopathy is a clinical diagnosis characterized by the presence of left ventricular dilatation and systolic disfunction unexplained by abnormal loading conditions or coronary artery disease.
Kristian Galanti, Ghaith Sharaf Dabbagh, Fabrizio Ricci, Sabina Gallina, Roberta Giansante, Ron Jacob, Edmond Obeng‐Gyimah, Leslie T. Cooper Jr, Sanjay K. Prasad, David H. Birnie, Andrew P. Landstrom, Selma F. Mohammed, Saidi Mohiddin, Mohammed Y. Khanji, Anwar A. Chahal   +14 more
wiley   +1 more source

Experimental aspects of cobalt cardiomyopathy

, 1971
G Róna
openalex   +1 more source

Pantethine therapy dramatically rescues end‐stage failing heart in a patient with deficiency of coenzyme A biosynthesis

ESC Heart Failure, EarlyView.
Violette Goetz, Bruno Lefort, Magalie Barth, Naïg Gueguen, Céline Bris, Emmanuelle Blanchard, Isabelle Benz‐de Bretagne, Hélène Blasco, Marine Tardieu, François Labarthe   +9 more
wiley   +1 more source

Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real‐world data analysis

ESC Heart Failure, EarlyView.
Abstract Aims and Background Cardiac amyloidosis leads to functional cardiac impairment and heart failure. Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the most common form. After initial suspicion, diagnosis involves imaging techniques, biopsy and genetic tests, prompting transthyretin stabilizer therapy to slow disease progression.
Julia Vogel, Sophia Jura, Stephan Settelmeier, Florian Buehning, Tobias Lerchner, Alexander Carpinteiro, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Utility of Cardiac CT for Cardiomyopathy Phenotyping. [PDF]

Tomography
Ibrahim R, Abdelnabi M, Pathangey G, Farina J, Lester SJ, Ayoub C, Alsidawi S, Tamarappoo BK, Jokerst C, Arsanjani R.   +9 more
europepmc   +1 more source

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design

ESC Heart Failure, EarlyView.
Abstract Aims Heart failure (HF) is one of today's leading public health issues worldwide. The sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin recently received a label expansion. It is now approved for treatment of HF across the entire spectrum of ejection fraction (EF) in Germany. However, real‐world data are limited.
Matthias Paul, Ralph Bosch, Behrus Subin, Angelika Guth, Marlena Mueller, Mareike Seelinger, Stephanie Riemann, Birgit Assmus   +7 more
wiley   +1 more source

Non-coding RNAs affecting NLRP3 inflammasome pathway in diabetic cardiomyopathy: a comprehensive review of potential therapeutic options. [PDF]

J Transl Med
Radmehr E, Yazdanpanah N, Rezaei N.
europepmc   +1 more source

Lower NT‐proBNP plasma concentrations in Pacific peoples with heart failure

ESC Heart Failure, EarlyView.
NT‐proBNP plasma concentrations were measured in participants of two NZ HF cohorts and were significantly lower in Pacific peoples and Māori compared with NZ Europeans. After accounting for age, sex, BMI, eGFR, LVEF and presence of AF, NT‐proBNP plasma concentrations remained significantly lower for Pacific peoples, but not for Māori.
Andree G. Pearson, John F. Pearson, Lynley K. Lewis, Allamanda Fa'atoese, Katrina K. Poppe, Chris Pemberton, Gerry Devlin, Mayanna Lund, A. Mark Richards, Richard Troughton, Robert N. Doughty   +10 more
wiley   +1 more source

Correction to: Family matters: health policies to tackle cardiomyopathies across Europe. [PDF]

Eur Heart J
europepmc   +1 more source